logo-loader
viewRyah Medtech Inc

RYAH Medtech report says pain the fourth most popular reason for medical cannabis patients to seek treatment

The report, based on data taken from RYAH’s propriety data pool, also said slightly more men than women treat their pain with cannabis

Ryah Medtech Inc - RYAH Medtech Inc issues report a chronic pain and cannabis, noting that pain is the 4th most popular reason medical cannabis patients seek treatment
In terms of strain preference, RYAH said patients rated Indica and Indica-dominant hybrids as providing the most symptom relief

RYAH Medtech Inc has issued a report on chronic pain and cannabis, noting that pain is the fourth most popular reason medical cannabis patients seek treatment. 

In a statement on Monday, the company said the report - which was based on data taken from RYAH’s propriety data pool - also showed that slightly more men than women treat their pain with cannabis.

Types of pain treated included migraines and headaches, general pain, arthritis and inflammation and fibromyalgia. Both groups of patients also experienced co-morbidities including anxiety, depression, stress, insomnia and mood swings.

READ: Ryah Medtech CEO Wagner says vaping's place is best reserved for the medicine cabinet

The study also looked at the data on how different types of chronic pain respond to different strains of medical cannabis. It noted that patients preferred strains with percentages of THC above 15%, considered to be a relatively high concentration of THC. 

RYAH said patients rated Indica and Indica-dominant hybrids as providing the most symptom relief. Examples of some of these Indica dominant strains include Blueberry, Diesel, Mango, and LA Confidential. Sativa is the other THC strain. 

CBD no major role symptom relief

One of the more unexpected findings was that CBD content did not seem to play a major role in terms of symptom relief, the company said.

"Pain is a top concern for medical cannabis patients visiting physicians and dispensaries and we hope that this report will help inform the public on how some patients are personalizing their cannabis treatments to achieve better outcomes,” said RYAH CEO Gregory Wagner.

“As a company rooted in big data and predictive analysis, RYAH is uniquely positioned to use our artificial intelligence platform to provide insights on the complete medical plant life cycle from seed to consumption,” he added.

RYAH, based in New York, is a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry. It has also developed the first dose-measuring cannabis vaporizer.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ryah Medtech Inc named herein, including the promotion by the Company of Ryah Medtech Inc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

RYAH Medtech stocks the shelves with its cannabis vaporizer at Maryland...

RYAH Medtech Inc Head of Marketing and Communications Sofiya Kleschuk and Director of Product Operations Jordan Medley join Maryland Sweetspot Dispensary Manager Peter Franklin to tell Proactive Investors the two have joined forces to begin offering RYAH vaporizers to medical...

on 07/11/2019

2 min read